DB
AUTL

Dmitry Balyasny’s Autolus Therapeutics AUTL Stock Holding History

Dmitry Balyasny’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
972,748
+1,057
+0.1% +$1.66K ﹤0.01% 1954
2026
Q1 		$1.34M Buy
+971,691
New +$1.48M ﹤0.01% 1953
2024
Q3 		– Sell
-22,242
Closed -$77.4K – 2732
2024
Q2 		$77.4K Sell
22,242
-38,686
-63% -$167K ﹤0.01% 2417
2024
Q1 		$389K Buy
+60,928
New +$380K ﹤0.01% 2161
2018
Q3 		– Sell
-50,000
Closed -$1.34M – 1654
2018
Q2 		$1.34M Buy
+50,000
New +$1.32M 0.01% 1056

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dmitry Balyasny's AUTL Position: Q2 2026 in Review

Dmitry Balyasny increased its Autolus Therapeutics (AUTL) stake by 0.11% in Q2 2026, buying an estimated $1.66K and bringing the position to 972,748 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Dmitry Balyasny first reported a position in AUTL in Q2 2018 and has held it in 5 quarters since. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Dmitry Balyasny held 972,748 shares of Autolus Therapeutics worth $1.56M as of Q2 2026.
  • Dmitry Balyasny bought 1,057 Autolus Therapeutics shares in Q2 2026, an estimated $1.66K.
  • Autolus Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1954 holding.
  • Dmitry Balyasny first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 5 quarters since.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.